Ketohexokinase Antibody (TT-I): sc-100381
- Ketohexokinase Antibody (TT-I) is a mouse monoclonal IgG2a κ provided at 100 µg/ml
- raised against recombinant Ketohexokinase of human origin
- recommended for detection of Ketohexokinase isoforms A and C of human origin by WB, IP, IF, IHC(P) and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Ketohexokinase Antibody (TT-I). This work is in progress.
QUICK LINKS
SEE ALSO...
Ketohexokinase Antibody (TT-I) is a mouse monoclonal IgG2a antibody that detects Ketohexokinase in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Ketohexokinase plays a crucial role in the metabolism of dietary fructose, catalyzing the conversion of fructose to fructose-1-phosphate, which is essential for energy production and metabolic regulation. Ketohexokinase is predominantly expressed in the kidney, liver, pancreas, and spleen, highlighting its importance in processing dietary sugars and maintaining metabolic homeostasis. The localization of Ketohexokinase in these organs is vital, as it ensures efficient fructose metabolism, which is particularly important given the rising prevalence of fructose consumption in modern diets. Mutations in the KHK gene, which encodes for Ketohexokinase, can lead to fructosuria, a benign metabolic disorder characterized by the excretion of fructose in urine, underscoring the enzyme′s significance in human health. Anti-Ketohexokinase antibody (TT-I) is an invaluable tool for researchers studying fructose metabolism and its implications in metabolic disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Ketohexokinase Antibody (TT-I) References:
- The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma. | Hwa, JS., et al. 2006. Proteomics. 6: 1077-84. PMID: 16372272
- The purification and properties of human liver ketohexokinase. A role for ketohexokinase and fructose-bisphosphate aldolase in the metabolic production of oxalate from xylitol. | Bais, R., et al. 1985. Biochem J. 230: 53-60. PMID: 2996495
- Ketohexokinase-A acts as a nuclear protein kinase that mediates fructose-induced metastasis in breast cancer. | Kim, J., et al. 2020. Nat Commun. 11: 5436. PMID: 33116123
- Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. | Shepherd, EL., et al. 2021. JHEP Rep. 3: 100217. PMID: 33490936
- Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. | Gutierrez, JA., et al. 2021. Mol Metab. 48: 101196. PMID: 33667726
- Ketohexokinase-mediated fructose metabolism is lost in hepatocellular carcinoma and can be leveraged for metabolic imaging. | Tee, SS., et al. 2022. Sci Adv. 8: eabm7985. PMID: 35385296
- Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study. | Buziau, AM., et al. 2023. Gut. 72: 604-606. PMID: 35537810
- Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial. | Kazierad, DJ., et al. 2021. Med. 2: 800-813.e3. PMID: 35590219
- Ketohexokinase-dependent metabolism of cerebral endogenous fructose in microglia drives diabetes-associated cognitive dysfunction. | Li, Y., et al. 2023. Exp Mol Med. 55: 2417-2432. PMID: 37907746
- Safety and efficacy of pharmacological inhibition of ketohexokinase in hereditary fructose intolerance. | Koene, EJ., et al. 2025. J Clin Invest. 135: PMID: 39932807
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ketohexokinase Antibody (TT-I) | sc-100381 | 100 µg/ml | $339.00 |